Aktieanalys

Medivir Q2 2024: Licensing Deal after ESMO? - Redeye

{newsItem.title}

Redeye Publicerad: 23 Aug 2024 07:32

Redeye comments on Medivir's Q2 report. The main event in the quarter was the presentation of an estimated mean TTP of 10.8 months for fostrox in liver cancer. The next catalyst will be updated fostrox data at ESMO in mid-September.

Länk till analysen i sin helhet: https://www.redeye.se/research/1032965/medivir-q2-2024-licensing-deal-after-esmo?utm_source=finwire&utm_medium=RSS

Nyheter om Medivir

Läses av andra just nu

Om aktien Medivir

Senaste nytt